Adaptimmune Therapeutics (ADAP.US): The 2024 Q1 financial report achieved revenue of $56.78 million, previous value of USD 476.01 million, expected value of USD 10.73 million; earnings per share were -0.18 USD, previous value was USD 0.00, and expected value was -0.10 USD.
Adaptimmune Therapeutics(ADAP.US)：2024年Q1财报实现营收567.8万美元，前值为4760.1万美元，预期值为1073万美元；每股收益为-0.18美元，前值为0.00美元，预期值为-0.10美元。
Adaptimmune Therapeutics (ADAP.US): The 2024 Q1 financial report achieved revenue of $56.78 million, previous value of USD 476.01 million, expected value of USD 10.73 million; earnings per share were -0.18 USD, previous value was USD 0.00, and expected va
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.